lncSNHG16 promotes hepatocellular carcinoma development by inhibiting autophagy.
- Published in:
- Clinical & Translational Oncology, 2025, v. 27, n. 4, p. 1612, doi. 10.1007/s12094-024-03730-y
- By:
- Publication type:
- Article
Works by Su, Jia-Yong
Results: 7
1
2
miR-17-5p slows progression of hepatocellular carcinoma by downregulating TGFβR2.
- Published in:
- Clinical & Translational Oncology, 2023, v. 25, n. 10, p. 2960, doi. 10.1007/s12094-023-03164-y
- By:
- Publication type:
- Article
3
Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis.
- Published in:
- BJS Open, 2023, v. 7, n. 1, p. 1, doi. 10.1093/bjsopen/zrac167
- By:
- Publication type:
- Article
4
Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future.
- Published in:
- Expert Opinion on Investigational Drugs, 2022, v. 31, n. 11, p. 1151, doi. 10.1080/13543784.2022.2151891
- By:
- Publication type:
- Article
5
Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study.
- Published in:
- Infectious Agents & Cancer, 2024, v. 19, n. 1, p. 1, doi. 10.1186/s13027-024-00575-6
- By:
- Publication type:
- Article
6
Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study.
- Published in:
- Infectious Agents & Cancer, 2024, v. 19, n. 1, p. 1, doi. 10.1186/s13027-024-00575-6
- By:
- Publication type:
- Article
7
Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomy.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 8, p. 842, doi. 10.1111/apt.17668
- By:
- Publication type:
- Article